NASDAQ:CRIS - Curis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.80
  • Forecasted Upside: 169.75 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.34
▲ +0.05 (0.69%)

This chart shows the closing price for CRIS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Curis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRIS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRIS

Analyst Price Target is $19.80
▲ +169.75% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Curis in the last 3 months. The average price target is $19.80, with a high forecast of $24.00 and a low forecast of $15.00. The average price target represents a 169.75% upside from the last price of $7.34.

This chart shows the closing price for CRIS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Curis.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021Raymond JamesInitiated CoverageOutperform$15.00High
8/4/2021B. RileyReiterated RatingBuy$22.00Medium
6/14/2021HC WainwrightReiterated RatingBuy$20.00High
6/14/2021B. RileyReiterated RatingBuy$22.00Medium
5/13/2021B. RileyBoost Price TargetPositive ➝ Buy$19.00 ➝ $22.00High
5/13/2021Cantor FitzgeraldBoost Price TargetOverweight$15.00 ➝ $24.00High
3/24/2021B. RileyInitiated CoverageBuy$19.00High
3/17/2021JonestradingBoost Price TargetBuy$14.00 ➝ $18.00High
1/15/2021HC WainwrightBoost Price TargetBuy$9.00 ➝ $16.00N/A
12/16/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$4.00 ➝ $15.00Low
12/8/2020HC WainwrightBoost Price TargetBuy$5.00 ➝ $9.00N/A
11/24/2020HC WainwrightInitiated CoverageBuy$5.00Medium
7/29/2020LaidlawInitiated CoverageBuy$5.00Medium
7/16/2020Cantor FitzgeraldInitiated CoverageOverweight$4.00 ➝ $4.00High
9/25/2018CowenReiterated RatingBuyMedium
8/6/2018CowenReiterated RatingBuyMedium
8/3/2018SunTrust BanksLower Price TargetBuy$8.00High
5/7/2018Robert W. BairdLower Price TargetOutperform ➝ Outperform$30.00Low
10/23/2017GuggenheimInitiated CoverageBuy$35.00N/A
5/15/2017CowenReiterated RatingBuyN/A
5/5/2017CowenReiterated RatingBuyLow
3/22/2017CowenReiterated RatingBuyMedium
3/11/2017FBR & Co.Set Price TargetBuy$30.00Low
3/7/2017FBR & Co.Reiterated RatingOutperformLow
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/24/2021
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/24/2021

Current Sentiment

  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Curis logo
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $7.34
Low: $7.05
High: $7.35

50 Day Range

MA: $7.98
Low: $7.07
High: $8.85

52 Week Range

Now: $7.34
Low: $1.06
High: $17.40

Volume

819,137 shs

Average Volume

2,312,212 shs

Market Capitalization

$672.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Curis?

The following Wall Street analysts have issued reports on Curis in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, Jonestrading, Raymond James, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CRIS.

What is the current price target for Curis?

5 Wall Street analysts have set twelve-month price targets for Curis in the last year. Their average twelve-month price target is $19.80, suggesting a possible upside of 169.8%. Cantor Fitzgerald has the highest price target set, predicting CRIS will reach $24.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $15.00 for Curis in the next year.
View the latest price targets for CRIS.

What is the current consensus analyst rating for Curis?

Curis currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRIS will outperform the market and that investors should add to their positions of Curis.
View the latest ratings for CRIS.

How do I contact Curis' investor relations team?

Curis' physical mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (617) 503-6500 and its investor relations email address is [email protected] The official website for Curis is www.curis.com.